New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
04:55 EDTAET, AET, AET, RNA, RNA, RNA, SHPG, SHPG, SHPG, ALXN, ALXN, ALXN, MSTX, MSTX, MSTX, NVS, NVS, NVS, SRPT, SRPT, SRPT, GENZ, GENZ, GENZ, FOLD, FOLD, FOLD, RXII, RXII, RXII, PFE, PFE, PFE, HUM, HUM, HUMTerrapinn to hold a conference
World Orphan Drug Congress is being held in Washington, D.C. on April 23-25.
News For HUM;PFE;RXII;FOLD;GENZ;SRPT;NVS;MSTX;ALXN;SHPG;RNA;AET From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 27, 2015
13:15 EDTAETEarnings Watch: Aetna to report Q1 results amid continued membership growth
Aetna (AET) is scheduled to report first quarter earnings before the market open on Tuesday, April 28 with a conference call scheduled for 8:00 am ET. Aetna operates as a diversified health care benefits company in the United States. The company operates in three segments: Health Care, Group Insurance, and Large Case Pensions. EXPECTATIONS: Analysts are looking for earnings per share of $1.95 on revenue of $15.46B, according to First Call. The consensus range for EPS is $1.87-$2.13 on revenue of $15.08B-$16.0B. LAST QUARTER: Aetna reported fourth quarter EPS of $1.22, which was in-line with consensus estimates, on revenue of $14.77B against estimates of $14.6B. The company raised its fiscal 2015 EPS view to at least $7.00, against consensus estimates at the time of $7.16. "Aetna achieved record annual operating revenue and operating earnings in 2014, and delivered full-year operating earnings per share at the high end of our most recent projection," said Aetna chairman and CEO Mark Bertolini. "Our 2014 operating earnings-per-share results represent an increase of more than 7% over 2013 and a compound annualized growth rate of 15% since 2010. We also ended the year serving more than 23.5M medical members, an increase of approximately 1.4M members from 2013." STREET RESEARCH: On March 19, Sterne Agee upgraded Aetna to Buy from Neutral. The firm says that the company is the best-positioned name within the large-cap health plan space, a defensive sector that has little exposure to Europe and reasonable growth prospects, according to the firm. On March 12, Argus increased its price target on Aetna to $115 from $103 after Aetna's Q4 membership growth exceeded its prior targets. The firm said it thinks the company will deliver sustained membership and revenue growth in 2015. It kept a Buy rating on the stock. PRICE ACTION: Aetna shares are up approximately 17% since the company's last earnings report on February 3 and are down over 1% in afternoon trading ahead of Tuesday morning's earnings.
12:47 EDTPFEPfizer technical comments before earnings
Subscribe for More Information
10:30 EDTNVSNovartis says Phase III Arzerra study met primary endpoint
Subscribe for More Information
09:03 EDTPFEChina Jo-Jo Drugstore signs incentive agreement with Pfizer subsidiary
China Jo-Jo Drugstores (CJJD) announced its subsidiary, Hangzhou Jiuzhou Grand Pharmacy Chain, has signed a new sales incentive agreement with Wyeth Pharmaceutical, a wholly owned subsidiary in China of Pfizer (PFE). The Agreement illustrated specific approaches and conditions of Jiuzhou Pharmacy's collaboration with Wyeth, including sales targets, promotional incentive to consumers, products and pricing methods. In return, Wyeth will fully support Jiuzhou Pharmacy with priority delivery, favorable purchase prices and promotional activities.
08:41 EDTPFETelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
08:26 EDTALXNAlexion coverage assumed with an Outperform at Oppenheimer
Subscribe for More Information
06:19 EDTPFE, NVSPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
10:01 EDTMSTXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:33 EDTALXNAlexion has reached attractive entry point, says SunTrust
Subscribe for More Information
08:00 EDTMSTXMast Therapeutics initiated with a Buy at Roth Capital
Target $3.
April 23, 2015
11:23 EDTALXNAlexion weakness a buying opportunity, says Cowen
09:52 EDTNVSEli Lilly sees at least $200M in savings from Novartis Animal Health acquisition
09:20 EDTSHPGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
06:41 EDTALXNAlexion backs FY15 non-GAAP EPS view $5.60-$5.80, consensus $5.87
Subscribe for More Information
06:39 EDTALXNAlexion reports Q1 non-GAAP EPS $1.28, consensus $1.33
Reports Q1 revenue $600.3M, consensus $591.38M. Reports Q1 net product sales of Soliris $600.3M vs. $566.6M a year ago.
05:25 EDTNVSNovartis backs FY15 revenue guidance of growth in mid-single digits
Subscribe for More Information
05:22 EDTNVSNovartis reports Q1 Core EPS $1.33, consensus $1.10
Subscribe for More Information
April 22, 2015
15:50 EDTALXNNotable companies reporting before tomorrow's open
Subscribe for More Information
08:31 EDTHUMHumana realigns financial reporting segments
Subscribe for More Information
07:07 EDTSHPGEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use